Universal reference book for medicines
Product name: AVIAMARIN (AVIAMARIN)

Active substance: dimenhydrinate

Type: The drug used in kinetosis

Manufacturer: ФП ОБОЛЕНСКОЕ (Russia)
Composition, form of production and packaging
?
Tablets are white or almost white, round, flat-cylindrical, with a facet and a risk.
1 tab.

dimenhydrinate 50 mg

Excipients: microcrystalline cellulose - 40 mg, povidone - 4 mg, crospovidone - 10 mg, mannitol - 90 mg, silicon dioxide colloid (aerosil) - 4 mg, magnesium stearate - 2 mg.

5 pieces.
- packings of cellular contour (1) - packs cardboard.
5 pieces.
- packings cellular planimetric (2) - packs cardboard.
10 pieces.
- packings of cellular contour (1) - packs cardboard.
10 pieces.
- packings cellular planimetric (2) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2016.

PHARMACHOLOGIC EFFECT

The blocker of histamine H 1 -receptors.
It blocks histamine H 1 -receptors and m-cholinergic receptors of the central nervous system. Oppresses the vestibular apparatus of the inner ear, acting primarily on the otoliths, in high doses - on the semicircular canals. The main effect of dimenhydrinate is realized due to blockade of m-cholinergic receptors.Has antiemetic, sedative effect, eliminates dizziness.
PHARMACOKINETICS

After ingestion, dimenhydrinate is well absorbed, distributed to organs and tissues.
The effect of the drug manifests itself after 15-30 minutes and persists for 3-6 hours. About 78% of dimenhydrinate binds to blood plasma proteins. Dimenhydrinate is metabolized in the liver and is almost completely excreted in the urine for 24 hours. Small amounts are excreted in breast milk. T 1/2 dimenhydrinate is about 3.5 h.
INDICATIONS

- sea and air sickness;

- prevention and treatment of symptoms of vestibular and labyrinthine disorders (dizziness, nausea, vomiting), except for symptoms caused by antitumor therapy;

- symptomatic therapy of Meniere's disease.

DOSING MODE

Is taken orally, before eating.

Marine and airborne disease

For the prevention of motion sickness, the first dose should be taken 30-60 minutes before the movement.

Children aged 6-12 years:
on 1 / 2-1 tab. (25-50 mg) every 6-8 hours, but not more than 3 tab. (150 mg) for 24 hours.
Adults and children 12 years and older:
on 1-2 tab. (50-100 mg) every 4-6 hours, but not more than 8 tablets. (400 mg) for 24 hours.
Prevention and treatment of symptoms of vestibular and labyrinthine disorders (dizziness, nausea, vomiting), with the exception of symptoms caused by antitumor therapy

Children aged 6-12 years: 1 / 2-1 tab.
(25-50 mg) every 6-8 hours, but not more than 3 tab. (150 mg) for 24 hours.
Adults and children over 12 years: 1-2 tablespoons.
(50-100 mg) every 4-6 hours, but not more than 8 tablets. (400 mg) for 24 hours.
Symptomatic therapy of Ménière's disease

Children aged 6-12 years: 1 / 2-1 tab.
(25-50 mg) every 6-8 hours, but not more than 3 tab. (150 mg) for 24 hours.
Adults and children over 12 years: 1-2 tablespoons.
(50-100 mg) every 4-6 hours, but not more than 8 tablets. (400 mg) for 24 hours.
For elderly patients, the drug should be taken at the lowest recommended adult dose.

The duration of the drug and the possibility of repeating the course of treatment - in consultation with the doctor.

SIDE EFFECT

Determination of the frequency of adverse reactions: very often (? 1/10 cases), often (? 1/100 and <1/10 cases), infrequently (? 1/1000 and <1/100 cases), rarely (? 1 / 10,000 and <1/1000 cases) and very rarely (<1/10 000 cases, including individual reports).

From the side of the central nervous system: very often - dizziness, drowsiness, impaired concentration;
often - general weakness, fatigue, anxiety, nervousness; rarely - headache, insomnia.
From the senses: often - the weakening of night and color vision, blurred vision, disruption of accommodation.

On the part of the digestive system: often - dry mouth, nausea, vomiting;
very rarely - a decrease in appetite.
From the respiratory system: infrequent - dryness of the mucous membrane of the nose and throat, thickening of the bronchial secretion.

From the cardiovascular system: rarely - lowering blood pressure, tachycardia.

Allergic reactions: rarely - skin rash, medical dermatitis;
very rarely - angioedema, bronchospasm.
From the urinary system: rarely - difficulty urinating.

Other: rarely - hemolytic anemia.

If any of the above adverse reactions are aggravated, or the patient has noticed any other undesirable phenomena, he should inform the doctor about it.

CONTRAINDICATIONS

- hypersensitivity to dimenhydrinate or other components of the drug;

- children's age till 6 years;

- the period of breastfeeding.

With caution: convulsive syndrome, zakratougolnaya glaucoma, prostatic hyperplasia, bronchial asthma, cardiovascular diseases, hyperthyroidism, stenosing peptic ulcer, pyloroduodenal obstruction and obstruction of the neck of the bladder.

PREGNANCY AND LACTATION

The use of the drug during pregnancy is possible only if the expected benefit for the mother exceeds the potential risk to the fetus.

The use of the drug in the period of breastfeeding is contraindicated.
If it is necessary to use the drug, breast-feeding should be discontinued.
APPLICATION FOR CHILDREN

Contraindication: children under 6 years.

APPLICATION IN ELDERLY PATIENTS

For elderly patients, the drug should be taken at the lowest recommended adult dose.

SPECIAL INSTRUCTIONS

When using dimenhydrinate, false-negative results of allergic tests are possible.
Allergic tests should be performed no earlier than 3 days after the end of the administration of dimenhydrate.
Dimenhydrinate may show a false increase in the level of theophylline in the blood when it is determined by the immunological method.

Dimenhydrinate can mask the symptoms of ototoxicity and contribute to the development of irreversible hearing loss, and therefore its simultaneous use with ototoxic antibiotics is not recommended.

Dimenhydrinate is metabolized in the liver, so care should be taken when using the drug in patients with hepatic insufficiency.

Impact on the ability to drive vehicles and manage mechanisms

Given the side effect of dimenhydrinate, caution should be exercised in driving vehicles and engaging in potentially hazardous activities requiring increased attention and speed of psychomotor reactions.

OVERDOSE

Symptoms: dry mouth, nose and throat, red face, slowed and shortness of breath, confusion, in children - convulsions, hallucinations.
If these symptoms appear, you should immediately call your doctor.
Treatment: washing the stomach with a suspension of activated carbon (20-30 g), the appointment of a salt laxative (10-15 grams of sodium sulfate), symptomatic therapy, with cramps in children - phenobarbital (5-6 mg / kg), diazepam.

DRUG INTERACTION

Dimenhydrinate enhances the effect of atropine, tricyclic antidepressants, catecholamines, barbiturates, ethanol, sedatives and hypnotics, antipsychotics.

Dimenhydrinate weakens the action of corticosteroids, anticoagulants.

Dimenhydrinate reduces the reaction to apomorphine.

Dimenhydrinate reduces the depressive effect of acetylcholine on the heart muscle.

Simultaneous reception of dimenhydrinate with bismuth preparations, scopolamine, anesthetics and psychotropic agents increases the likelihood of visual impairment.

The simultaneous use of the drug with ototoxic antibiotics (streptomycin, neomycin, biomycin, amikacin, kanamycin) is not recommended, t.
dimenhydrinate may mask the symptoms of ototoxicity and contribute to the development of irreversible hearing impairment.
TERMS OF RELEASE FROM PHARMACY

The drug is approved for use as a means of OTC.

TERMS AND CONDITIONS OF STORAGE

The drug should be stored out of reach of children, dry, protected from light at a temperature of no higher than 25 ° C.
Shelf life - 2 years.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!